메인메뉴바로가기

한양대학교 산학협력단

홈으로 바로가기 > 연구정보 > 연구성과 > Recent Articles

연구성과 > Recent Articles

  • 한양대학교 기관으로 출판된 최신 SCI급 논문현황 (Web Of Science에서 제공되는 자료)
  • 매주 1회 업데이트

SCI Article

Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary su
Author Min, Kyueng-Whan (Dept Pathol);
Corresponding Author Info Kwon, MJ (reprint author), Hallym Univ, Coll Med, Sacred Heart Hosp, Dept Pathol, Anyang Si 431070, Gyeonggi Do, South Korea.
E-mail mulank99@hallym.or.kr
Document Type Article
Source PATHOLOGY RESEARCH AND PRACTICE Volume:213 Issue:4 Pages:381-388 Published:2017
Times Cited 0
External Information http://dx.doi.org/10.1016/j.prp.2017.01.004
Abstract Hepatocyte growth factor (HGF) and MET are candidates of targeted therapies for cancer patients. Although MET and HGF are commonly expressed in biliary tract cancers, their expression and gene copy number status and their association with KRAS mutations have not been investigated in pancreatobiliary-type ampullary adenocarcinomas (A-ACs), one of the aggressive periampullary cancers. MET and HGF expressions and MET copy number status were examined by performing immunohistochemistry (IHC) and silver in situ hybridization (SISH) in 62 surgically resected, paraffin-embedded tumors, respectively. High MET and HGF protein expressions were detected in 24 (38.7%) and 15 (24.2%) tumors. High MET expression was associated with KRAS mutation. However, there were no associations of high MET/HGF expression alone with other clinicopathological feature or survival. MET SISH positivity was detected in 19 tumors (30.6%), where 84.2% were due to high trisomy or polysomy and only 3 cases (15.8%) were MET gene amplification. The overall MET protein overexpression was well correlated with METSISH positivity. The concurrent MET SISH positivity and KRAS mutation, not each alone, was an independent poor prognostic factor of disease-free survival only in pancreatobiliary subtype of A-ACs, but not in intestinal subtype. Concurrent MET SISH positivity and KRAS mutation may predict a high risk of recurrence in pancreatobiliary subtype of A-ACs, indicating those markers could be potent candidates for a new therapeutic target in this cancer type. MET IHC can be used as a reliable tool screening for MET copy number status in ampullary cancers. (C) 2017 Elsevier GmbH. All rights reserved.
Web of Science Categories Pathology
Funding Hallym University Research Funds [HURF-2015-08, HURF-2016-40]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2016R1D1A1B03935447]
Language English
리스트
관리자페이지 바로가기